Adverse effects of biological therapy in rheumatology

Česká verzia

Authors: Marta Olejárová
Authors place of work: Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
Published in the journal: Vnitř Lék 2016; 62(7-8): 605-612
Category: Reviews

Summary

The biological treatment which is the most effective type of therapy for inflammatory rheumatic diseases, has become part of a standard clinical rheumatology practice in recent years. Thousands of patients in the Czech Republic with rheumatoid arthritis, different forms of spondyloarthritides and with psoriatic arthritis are now successfully treated in this way. The following medications are registered in the Czech Republic for the treatment of rheumatic diseases: infliximab, adalimumab, golimumab, certolizumab pegol, etanercept, abatacept, rituximab, tocilizumab and belimumab, newly also secukinumab. This effective therapy also entails a new spectrum of adverse effects, different to those of the synthetic disease modifying antirheumatic drugs. The most frequent problems include a higher incidence of infections including exacerbation of latent tuberculosis, further we can meet hematological, gastroenterological and immunological abnormalities some of which, luckily of rare occurrence, may have a very serious character. The cardiovascular risk is rather reduced during long-term therapy, however in patients with chronic heart failure the anti-TNF therapy may lead to its worsening. All physicians caring for patients with inflammatory rheumatic diseases should have the basic knowledge of the range of the adverse effects.

Key words:
abatacept – adalimumab – ankylosing spondylitis – biological treatment – certolizumab pegol – golimumab – TNFα inhibitors – infliximab – adverse effects – psoriatic arthritis – rheumatoid arthritis – rituximab – secukinumab – tocilizumab

Zdroje

1. Olejárová M. Biologická léčba v revmatologii. Mladá Fronta: Praha 2010. ISBN 978–80–204–2281–1.

2. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66(10): 1339–1344.

3. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52(11): 3403–3412.

4. Curtis JR, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56(4): 1125–1133.

5. Ramiro S, Gaujoux-Viala C, Nam JL et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73(3): 529–535.

6. Askling J, Fored CM, Brandt L et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52(7): 1986–1992.

7. Dixon WG, Hyrich KL, Watson KD et al. [B S R B R Control Centre Consortium]. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69(3): 522–528.

8. Gómez-Reino JJ, Carmona L, Angel Descalzo M. [Biobadaser Group]. .Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57(5): 756–761.

9. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60(7): 1884–1894.

10. Gómez-Reino JJ, Carmona L, Angel Descalzo M. [Biobadaser Group]. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57(5): 756–761.

11. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al. [BIOBADASER Group]. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52(6): 1766–1772.

12. Atzeni F, Sarzi-Puttini P, Mutti A et al. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013; 12(12): 1115–1117.

13. Faurschou M, Jayne DR. Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med 2014; 65: 263–278. Dostupné z DOI: <http://dx.doi.org/10.1146/annurev-med-070912–133235>.

14. Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014; 91: 56–64. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.140103>.

15. Bessissow T, Renard M, Hoffman I et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012; 36(4): 312–323.

16. Bathon A, Martin RW, Fleischmann RM. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22): 1586–1593. Erratum in N Engl J Med 2001; 344(1): 76. N Engl J Med 2001; 344(3): 240.

17. Rajakulendran S, Gadsby K, Allen D et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis 2006; 65(12): 1678–1679.

18. Metyas SK, Tadros RM, Arkfeld DG. Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 2009; 29(4): 437–439.

19. Tyler LN, Harville TO, Blackall DP. Multiple alloantibodies after transfusion in an infant treated with infliximab. N Engl J Med 2007; 357(20): 2092–2093.

20. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003; 30(2): 401–403.

21. Huizinga TW, Fleischmann RM, Jasson M et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014; 73(9): 1626–1634.

22. Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol 2014; 10(1): 159–169.

23. Lee Y, Kyung SY, Choi SJ et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006; 21(3): 183–186.

24. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39(5): 327–346.

25. Atzeni F, Gianturco L, Talotta R et al. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern? Immunotherapy 2015; 7(4): 353–361.

26. de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint Bone Spine 2016 Jun 21. pii: S1297–319X(16)30050–1. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2016.02.028>.

27. Iriarte A, Zaera C, Bachiller-Corral J et al. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol 2016 Mar 15. pii: S0210–5705(16)00088–1. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gastrohep.2016.01.011>.

28. Tanaka T, Hishitani Y, Ogata A. Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics 2014; 8: 141–153. Dostupné z DOI: <http://dx.doi.org/10.2147/BTT.S37509>.

29. Nanau RM, Neuman MG. Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 2014; 17(3): 324–361.

30. Deepak P, Stobaugh DJ, Sherid M et al. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 2013; 38(4): 388–396.

31. Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 2012; 79(4): 351–355.

32. Keene DL, Legare C, Taylor E et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011; 38(4): 565–571.

33. Nguyen K, Vleugels RA, Velez NF et al. Psoriasiform reactions to anti-tumor necrosis factor α therapy. J Clin Rheumatol 2013; 19(7): 377–381.

34. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275–2285.

35. Vencovský J et al. Bezpečnost biologické léčby – doporučení České revmatologické společnosti. Čes Revmatol 2009; 17(3): 146–160